As a result of these mutations, the FLT3 receptor is perpetually activated in the absence of the FLT3 ligand (FLT3L), increasing proliferation and decreasing apoptosis [46,47], making FLT3 an excellent target for cancer therapies. The gene discussed is FLT3; the disease is cancer.